Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MAP2K1 |
Variant | R49L |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | MAP2K1 R49L lies within the negative regulatory region of the Map2k1 protein (PMID: 24241536). R49L confers a gain of function to the Map2k1 protein as demonstrated by transforming ability in culture and in vivo, and phosphorylation of Erk1/2 (PMID: 22327936). |
Associated Drug Resistance | |
Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 R49L |
Transcript | NM_002755.4 |
gDNA | chr15:g.66435092G>T |
cDNA | c.146G>T |
Protein | p.R49L |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002755 | chr15:g.66435092G>T | c.146G>T | p.R49L | RefSeq | GRCh38/hg38 |
NM_002755.4 | chr15:g.66435092G>T | c.146G>T | p.R49L | RefSeq | GRCh38/hg38 |
XM_017022411 | chr15:g.66435092G>T | c.146G>T | p.R49L | RefSeq | GRCh38/hg38 |
XM_017022411.2 | chr15:g.66435092G>T | c.146G>T | p.R49L | RefSeq | GRCh38/hg38 |
NM_002755.3 | chr15:g.66435092G>T | c.146G>T | p.R49L | RefSeq | GRCh38/hg38 |
XM_017022411.3 | chr15:g.66435092G>T | c.146G>T | p.R49L | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 R49L | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited viability of a transformed cell line expressing MAP2K1 R49L in culture (PMID: 36442478). | 36442478 |